3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
19
Phase 3
2
Phase 2
2
Phase 1
2
Phase EARLY_PHASE1
1
Phase 4
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
8
Gastrointestinal
7
Head & Neck
6
Breast
6
Thoracic
4
Other
4
Plasma cell
3
Other hematologic neoplasm
3
Myeloid
3
Lymphoid
3
CNS
3
Sarcoma
2
Other neoplasm
2
Gynecologic
2
Classical hematology
2
Tumor-Agnostic
1
Dermatologic
1
Conditions
Uterine Cervical Neoplasms
1
Ovarian Neoplasms
1
Fallopian Tube Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Interventions
Paclitaxel
233
Carboplatin
217
Bevacizumab
139
Cisplatin
134
pembrolizumab
89
Gemcitabine
69
olaparib
54
Docetaxel
47
Topotecan
44
Radiotherapy
43
liposomal doxorubicin
41
Taxes
41
niraparib
38
Cyclophosphamide
36
Doxorubicin
30
Letrozole
28
Drug Therapy
28
Nivolumab
27
Magnetic Resonance Spectroscopy
25
Immunoglobulin G
25
Disulfides
24
Oxaliplatin
23
durvalumab
22
Albumin-Bound Paclitaxel
22
apatinib
21
Etoposide
21
Brachytherapy
21
lenvatinib
20
Specimen Handling
20
Filgrastim
20
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Surveys and Questionnaires
×
Gynecologic
×
Clear all
NCT07276360
2026-03-27
HypoRTCx-UG
Uganda Cancer Institute
Phase 2
Recruiting
278 enrolled
NCT02124421
2024-11-19
CRS/HIPEC
Mercy Medical Center
Phase 2
Active not recruiting
32 enrolled